{"id":2709,"date":"2026-08-26T12:00:00","date_gmt":"2026-08-26T16:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2709"},"modified":"2026-08-26T23:52:50","modified_gmt":"2026-08-27T03:52:50","slug":"fda-approves-rasonque-first-broad-ras-targeted-therapy-for-pancreatic-cancer","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2709","title":{"rendered":"FDA Approves Rasonque, First Broad RAS-Targeted Therapy, for Pancreatic Cancer"},"content":{"rendered":"

Company:<\/strong> Revolution Medicines · Drug:<\/strong> Rasonque (Daraxonrasib) · Indication:<\/strong> Metastatic Pancreatic Adenocarcinoma · Event Type:<\/strong> FDA Approval · Date:<\/strong> August 26, 2026<\/p>\n

\"20260826_Revolution_Medicines_Rasonque_Therapeutic_Indications\"<\/p>\n

Summary<\/h4>\n

FDA approved Revolution Medicines’ once-daily oral Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. In the 500-patient randomized RASolute 302 study, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with investigator-selected chemotherapy, with a stratified hazard ratio of 0.40. The approval establishes the first broad RAS-targeted medicine in pancreatic cancer and validates active-state RAS tri-complex inhibition clinically. Safety, durability, access and performance outside the approved setting remain material constraints.<\/p>\n

What Happened<\/h4>\n

The approved label does not require a specific tumor RAS mutation. RASolute 302 enrolled an overall intent-to-treat population with and without an identified RAS alteration and randomized 248 patients to daraxonrasib and 252 to chemotherapy, with median follow-up at the February 10 data cutoff of 8.5 months. Daraxonrasib reduced the risk of death by 60%: median overall survival was 13.2 months versus 6.7 months (HR 0.40, 95% CI 0.30-0.53, p=4.6×10-11<\/sup>), and median progression-free survival was 7.2 versus 3.6 months (HR 0.49, 95% CI 0.38-0.64). Patient-reported analyses also favored daraxonrasib for time to worsening pain and global health status or quality of life. Grade 3 or higher treatment-emergent adverse events occurred in 62% versus 70% with chemotherapy, serious events in 30% versus 33%, and discontinuation due to an event in 3% versus 15%, though dose interruptions were frequent at 69%. Label warnings include dermatologic and soft-tissue toxicity, stomatitis, diarrhea, gastrointestinal perforation, interstitial lung disease or pneumonitis, and embryo-fetal toxicity.<\/p>\n

Deep Analysis<\/h4>\n

The overall-survival effect is unusually large for previously treated metastatic pancreatic cancer and was supported by randomized evidence, progression-free survival and patient-reported outcomes, so approval changes the treatment landscape more directly than a response-rate or single-arm signal would. It does not establish cure, benefit in localized disease, or superiority to first-line multiagent regimens. Mechanistically, daraxonrasib is a noncovalent RAS(ON) multi-selective tri-complex inhibitor designed to engage active, GTP-bound RAS through a ternary complex, differing from mutation-selective covalent inhibitors and potentially addressing the heterogeneous RAS genotypes that dominate pancreatic adenocarcinoma; clinical validation of the approved setting does not guarantee activity across all RAS-driven tumors or alleles. Commercial readiness is immediate in the United States, with a disclosed wholesale acquisition cost of $39,800 per 30-day supply, and access will depend on coverage, prior-therapy interpretation, toxicity management and community-oncology adoption.<\/p>\n

Company and Product Background<\/h4>\n

Pancreatic adenocarcinoma accounts for approximately 90-95% of pancreatic cancers and is commonly diagnosed after metastatic spread; most tumors are driven by activating RAS alterations, particularly KRAS. Historically, later-line care has relied on cytotoxic regimens with limited durability and considerable toxicity. Daraxonrasib is an oral RAS(ON) multi-selective inhibitor that stabilizes a tri-complex involving active RAS, preventing downstream signaling required for tumor growth and survival, with a broad design intended to address multiple common RAS genotypes rather than one mutant residue. Resistance may still emerge through pathway reactivation, altered nucleotide state, bypass signaling, lineage plasticity or pharmacologic limitations.<\/p>\n

Signal Extraction<\/h4>\n\n\n\n\n\n\n\n
Factor<\/th>\nAssessment<\/th>\n<\/tr>\n
Regulatory Scope<\/td>\nMetastatic pancreatic adenocarcinoma after ≥1 systemic therapy or unsuitable for multiagent therapy<\/td>\n<\/tr>\n
Overall Survival<\/td>\n13.2 vs 6.7 months; HR 0.40 in a 500-patient randomized Phase 3 study<\/td>\n<\/tr>\n
Disease Control<\/td>\nMedian PFS 7.2 vs 3.6 months; HR 0.49<\/td>\n<\/tr>\n
Safety<\/td>\nLower grade ≥3 events and discontinuation than chemotherapy; 69% required dose interruption<\/td>\n<\/tr>\n
Platform Read-Through<\/td>\nFirst approved broad active-state RAS tri-complex inhibitor<\/td>\n<\/tr>\n<\/table>\n

Reading the Signal<\/h4>\n

Bull case:<\/strong> Daraxonrasib establishes a new targeted standard for eligible previously treated metastatic pancreatic cancer and validates broad RAS(ON) inhibition, with a randomized survival advantage, concordant PFS and patient-reported outcomes, a mutation-agnostic label and immediate availability.<\/p>\n

Bear case:<\/strong> Follow-up is still relatively short (8.5 months median), toxicity management is substantial with 69% requiring dose interruption, and the approval should not yet be extrapolated to earlier-line, adjuvant or other RAS-driven tumor settings still under investigation.<\/p>\n

InSilens Take<\/h4>\n

Rasonque delivers a randomized overall-survival benefit in one of oncology’s most refractory settings and converts broad active-state RAS inhibition from a platform thesis into an approved treatment. The conclusion is intentionally bounded: the drug is not a cure, toxicity remains clinically important, and the approval does not validate every tumor, allele or earlier-line use in Revolution Medicines’ broader pipeline.<\/p>\n

Signal Assessment<\/h4>\n

Importance:<\/strong> 5\/5 · Direction:<\/strong> Positive · Confidence:<\/strong> High on facts, Moderate-High on interpretation<\/p>\n","protected":false},"excerpt":{"rendered":"

FDA approved Revolution Medicines’ once-daily oral Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. In the 500-patient randomized…<\/p>\n","protected":false},"author":1,"featured_media":2714,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[438,231,167,166],"class_list":["post-2709","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-daraxonrasib","tag-kras-driven-cancer","tag-pancreatic-cancer","tag-revolution-medicines"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2709","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2709"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2709\/revisions"}],"predecessor-version":[{"id":2719,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2709\/revisions\/2719"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2714"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2709"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2709"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2709"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}